Literature DB >> 22232092

Analysis & commentary: The US Preventive Services Task Force should consider a broader evidence base in updating its diabetes screening guidelines.

Christel Villarivera1, Julie Wolcott, Anjali Jain, Yiduo Zhang, Clifford Goodman.   

Abstract

Diabetes, especially type 2 diabetes, is on the rise throughout the United States. Several national health organizations and professional medical societies advocate screening people in high-risk groups for diabetes. However, the US Preventive Services Task Force recommends screening only adults with hypertension. We examined evidence supporting screening high-risk adults, including studies using intermediate outcomes and modeling studies. We found a broad range of evidence of practical relevance to diabetes screening that merits consideration in developing new screening guidelines. This evidence could inform recommendations to expand coverage to screening of other high-risk groups and could facilitate the prevention and early treatment of diabetes. We recommend that the US Preventive Services Task Force consider these expanded sources of evidence and revise its recommendations accordingly.

Entities:  

Mesh:

Year:  2012        PMID: 22232092     DOI: 10.1377/hlthaff.2011.0953

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Inadequacies of current approaches to prediabetes and diabetes prevention.

Authors:  Michael Bergman
Journal:  Endocrine       Date:  2013-07-24       Impact factor: 3.633

2.  Diabetes diagnosis and exercise initiation among older Americans.

Authors:  Leigh Ann Leung; Shailender Swaminathan; Amal N Trivedi
Journal:  Prev Med       Date:  2014-05-10       Impact factor: 4.018

3.  Screening for type 2 diabetes mellitus.

Authors:  Nasheeta Peer; Yusentha Balakrishna; Solange Durao
Journal:  Cochrane Database Syst Rev       Date:  2020-05-29

4.  Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes.

Authors:  Oscar H Roa Dueñas; Anna C Van der Burgh; Till Ittermann; Symen Ligthart; M Arfan Ikram; Robin Peeters; Layal Chaker
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.